Litcius/Paper detail

Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors

Pedram Razavi, Maura N. Dickler, Payal D. Shah, Weiyi Toy, David N. Brown, Helen Won, Bob T. Li, Ronglai Shen, Neil Vasan, Shanu Modi, Komal Jhaveri, Betty Ann Caravella, Sujata Patil, Pier Selenica, Stephen Zamora, Aimee Cowan, Elizabeth Comen, Andy Singh, Anne M. Covey, Michael F. Berger, Clifford A. Hudis, Larry Norton, Rebecca J. Nagy, Justin I. Odegaard, Richard B. Lanman, David B. Solit, Mark E. Robson, Mario E. Lacouture, Edi Brogi, Jorge S. Reis‐Filho, Mary Ellen Moynahan, Maurizio Scaltriti, Sarat Chandarlapaty

2020Nature Cancer163 citationsDOI

Topics & Concepts

PTENAromataseResistance (ecology)Aromatase inhibitorMedicineInternal medicineOncologyBiologyBreast cancerCancerPI3K/AKT/mTOR pathwayGeneticsSignal transductionEcologyPI3K/AKT/mTOR signaling in cancerChronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors | Litcius